---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-052940"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:38:36.260470+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AlloVir shareholders approve merger with Kalaris; combined co to trade as KLRS

## Summary
- Stockholders voted to approve merger: 3,543,715 for, 368,843 against, 282 abstain out of 3,912,840 votes cast.
- 2020 Plan amended: share reserve increased by 5% of post-merger outstanding; plan term extended to 10th anniversary of closing.
- Combined company to be renamed Kalaris Therapeutics, trading on Nasdaq under ticker KLRS after closing.
- Kalaris lead candidate TH103 (anti-VEGF fusion protein) in Phase 1 trial for neovascular AMD; plans for DME and RVO.

## SEC filing metadata
- accession: 0001193125-25-052940
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525052940/0001193125-25-052940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525052940/d347915d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-052940
- JSON: https://secwatch.observer/filing/0001193125-25-052940.json
- Plain text: https://secwatch.observer/filing/0001193125-25-052940.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.